Related Experiment Video
Updated: Aug 27, 2025
Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling
Qiulian Zhou1, Danni Meng1, Feng Li2
1Institute of Geriatrics (Shanghai University), Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong), School of Medicine, Shanghai University, Nantong 226011, China; Cardiac Regeneration and Ageing Lab, Institute of Cardiovascular Sciences, Shanghai Engineering Research Center of Organ Repair, School of Life Science, Shanghai University, Shanghai 200444, China.
Insights
Inhibiting Homeodomain-Interacting Protein Kinase 2 (HIPK2) protects the heart from pathological remodeling by reducing EGR3 and CLEC4D in cardiomyocytes and Smad3 phosphorylation in cardiac fibroblasts.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Cardiac Remodeling Research
Background:
- Homeodomain-Interacting Protein Kinase 2 (HIPK2) is known to maintain basal cardiac function.
- The specific role of HIPK2 in pathological cardiac remodeling is not fully understood.
Purpose of the Study:
- To investigate the role of HIPK2 in pathological cardiac remodeling.
- To elucidate the molecular mechanisms by which HIPK2 influences cardiac hypertrophy and fibrosis.
Main Methods:
- Utilized HIPK2 inhibitors and HIPK2 knockout mice subjected to transverse aortic constriction (TAC).
- Performed HIPK2 knockdown in neonatal rat cardiomyocytes (NRCMs), cardiac fibroblasts (NRCFs), and human embryonic stem cell-derived cardiomyocytes (hESC-CMs).
- Employed microarray analysis to identify HIPK2 targets, including EGR3 and CLEC4D, and investigated the roles of Smad3 phosphorylation.
Main Results:
- HIPK2 levels were elevated in TAC-induced cardiac hypertrophy and fibrosis models.
- HIPK2 inhibition, both pharmacological and genetic, improved cardiac function and suppressed hypertrophy and fibrosis.
- HIPK2 inhibition reduced cardiomyocyte hypertrophy and NRCF proliferation/differentiation by targeting EGR3, CLEC4D, and Smad3 phosphorylation.
Conclusions:
- HIPK2 inhibition confers protection against pathological cardiac remodeling.
- This protection is mediated by the downregulation of EGR3 and CLEC4D via ERK1/2-CREB signaling in cardiomyocytes.
- HIPK2 inhibition also suppresses cardiac fibroblast proliferation and differentiation through the inhibition of Smad3 phosphorylation.
Background:
Homeodomain-Interacting Protein Kinase 2 (HIPK2) has been reported to maintain basal cardiac function, however, its role in pathological cardiac remodeling remains unclear.
Methods:
HIPK2 inhibitors (tBID and PKI1H) treated mice and two lines of HIPK2-/- mice were subjected to transverse aortic constriction (TAC). HIPK2 knockdown were performed in neonatal rat cardiomyocytes (NRCMs), neonatal rat cardiac fibroblasts (NRCFs), and human embryonic stem cell-derived cardiomyocytes (hESC-CMs). Microarray analysis was used to screen HIPK2 targets. Overexpression of early growth response 3 (EGR3) and C-type lectin receptor 4D (CLEC4D) were performed in NRCMs, while an activator of Smad3 was used in NRCFs, to rescue the effects of HIPK2 knockdown. Finally, the effects of EGR3 and CLEC4D knockdown by AAV9 in TAC were determined.
Findings:
HIPK2 was elevated in TAC mice model, as well as cardiomyocyte hypertrophy and NRCFs fibrosis model. Pharmacological and genetic inhibition of HIPK2 improved cardiac function and suppressed cardiac hypertrophy and fibrosis induced by TAC. In vitro, HIPK2 inhibition prevented cardiomyocyte hypertrophic growth and NRCFs proliferation and differentiation. At the mechanistic level, we identified EGR3 and CLEC4D as new targets of HIPK2, which were regulated by ERK1/2-CREB and mediated the protective function of HIPK2 inhibition in cardiomyocytes. Meanwhile, inhibition of phosphorylation of Smad3 was responsible for the suppression of cardiac fibroblasts proliferation and differentiation by HIPK2 inhibition. Finally, we found that inhibition of EGR3 or CLEC4D protected against TAC.
Interpretation:
HIPK2 inhibition protects against pathological cardiac remodeling by reducing EGR3 and CLEC4D with ERK1/2-CREB inhibition in cardiomyocytes, and by suppressing the phosphorylation of Smad3 in cardiac fibroblasts.
Funding:
This work was supported by the grants from National Key Research and Development Project (2018YFE0113500 to J.X.), National Natural Science Foundation of China (82020108002 and 81911540486 to J.X., 81400647 to MJ Xu), the grant from Science and Technology Commission of Shanghai Municipality (21XD1421300 and 20DZ2255400 to J.X.), the "Dawn" Program of Shanghai Education Commission (19SG34 to J.X.), and Shanghai Sailing Program (21YF1413200 to Q.Z.).
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:29Heart Failure II: Pathophysiology
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:17Pathophysiology of Heart Failure